Energized Biogen Idec On Track For Two Filings In 2012
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen hopes to submit marketing applications in the U.S. and Europe for both MS therapy BG-12 and its therapies for hemophilia A and B in 2012, with launches possible in early and mid-2013.
You may also be interested in...
BG-12 In MS, Two Long-Acting Hemophilia Drugs Key To Scangos’ Revitalized Biogen Idec
An R&D overhaul trimmed 17 candidates from pipeline, but as several late-stage programs near potential approval, the biotech says it will resume focus on discovery and validation of new targets.
BG-12 In MS, Two Long-Acting Hemophilia Drugs Key To Scangos’ Revitalized Biogen Idec
An R&D overhaul trimmed 17 candidates from the pipeline, but as several late-stage programs near potential approval, the biotech says it will resume focus on discovery and validation of new targets.
Biogen Idec Buys Stromedix, Bringing IPF Candidate Full Circle
Started by a former Biogen executive, Stromedix licensed STX-100 from Biogen and developed it into an attractive candidate in an area the reshaped big biotech wants to pursue.